Recap: KalVista Pharma Q4 Earnings
Portfolio Pulse from Benzinga Insights
KalVista Pharma (NASDAQ:KALV) reported its Q4 earnings, beating estimated earnings by 18.09% with an EPS of $-0.77 versus an estimate of $-0.94. However, revenue was down $0 from the same period last year. Last quarter, the company beat on EPS by $0.23, which was followed by a 5.31% drop in the share price the next day.
July 07, 2023 | 11:10 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
KalVista Pharma beat Q4 earnings estimates but saw no increase in revenue compared to last year. Last quarter's earnings beat was followed by a drop in share price.
Despite beating earnings estimates, KalVista Pharma's share price may be negatively impacted due to no increase in revenue and the historical trend of share price dropping after beating earnings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100